ACM Global appoints Asia Pacific general manager

He will initially build ACM Global team in India

ACM Global Central Laboratory has announced the newest member of its Clinical Trials team, Nandan Rao as general manager, Asia Pacific. He will be located in Mumbai, India and initially will have oversight of trials conducted with ACM Global’s partner lab in the region.

Rao will also be building the ACM Global infrastructure and team throughout Asia Pacific.

Rao was formerly general manager of SRL, the largest clinical reference laboratory network in India and Southeast Asia, where he built the firm’s clinical trials operations.

‘Since establishing its presence in India in 2006, ACM has become a global leader in the central lab arena,’ said Elena Logan, VP of Clinical Trials at ACM Global Central Lab.

‘Nandan’s expertise in building a central lab group in this region will be of significant value to our organisation as we continue to expand ACM Global wholly owned locations.’

You may also like

Regulatory

ACM Global relocates European hq to expanded lab facilities

Moves into a new, state-of-the-art facility in York, UK
Regulatory

ACM Global Central Laboratory establishes Mumbai subsidiary

Operational facility is dedicated to managing clinical trials testing in India and study support in Asia Pacific
Finance

EMV Capital subsidiary Moirai acquires Destiny Pharma’s XF-73 antibiotic platform

The XF drug platform, designed to prevent bacterial resistance and combat Gram-positive infections such as MRSA, represents a high-impact addition to EMV’s life sciences portfolio
Regulatory

CHMP recommends Sanofi and Regeneron’s Dupixent to treat chronic spontaneous urticaria in EU

If approved, it would be the first targeted CSU therapy in the EU in more than a decade, supported by Phase III LIBERTY-CUPID data showing significant itch and hive reduction at 24 weeks
Finance

ScaleReady awards nearly $2m in G-Rex grants to advance cell and gene therapy manufacturing in California

The initiative supports leading academic GMP facilities in developing scalable, cost-effective platforms for CAR-T and other cell therapies, reinforcing California’s position as a global hub for CGT innovation
Regulatory

Biocon Biologics wins FDA approval for Bosaya and Aukelso, denosumab biosimilars to Prolia and Xgeva

The approvals mark a major step in Biocon’s mission to deliver affordable, high-quality biologics, with Bosaya offering a cost-effective treatment for osteoporosis and Aukelso expanding access to oncology care for patients with bone-related complications
Finance

Bio Protocol raises $6.9m to launch AI-powered decentralised science platform

The new platform enables researchers and patients to create "BioAgents" — autonomous AI co-scientists — to bring a faster, blockchain-verified path from lab to market
Subscribe now